Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population.
Hambardzumyan K, Hermanrud C, Marits P, Vivar N, Ernestam S, Wallman JK, van Vollenhoven RF, Fogdell-Hahn A, Saevarsdottir S; SWEFOT study group. Hambardzumyan K, et al. Scand J Rheumatol. 2019 Sep;48(5):362-366. doi: 10.1080/03009742.2019.1602670. Epub 2019 Jun 27. Scand J Rheumatol. 2019. PMID: 31244356 Free article. Clinical Trial.
Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion.
van Vollenhoven RF, Bolce R, Hambardzumyan K, Saevarsdottir S, Forslind K, Petersson IF, Sasso EH, Hwang CC, Segurado OG, Geborek P. van Vollenhoven RF, et al. Among authors: hambardzumyan k. Arthritis Rheumatol. 2015 Nov;67(11):2855-60. doi: 10.1002/art.39274. Arthritis Rheumatol. 2015. PMID: 26213309 Free PMC article.
Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies.
Curtis JR, Brahe CH, Østergaard M, Lund Hetland M, Hambardzumyan K, Saevarsdottir S, Wang X, Flake Ii DD, Sasso EH, Huizinga TW. Curtis JR, et al. Among authors: hambardzumyan k. Curr Med Res Opin. 2019 Sep;35(9):1483-1493. doi: 10.1080/03007995.2019.1585064. Epub 2019 Mar 14. Curr Med Res Opin. 2019. PMID: 30777458 Free article.
Response to: 'MBDA: what is it good for?' by Yazici et al.
van Vollenhoven R, Hambardzumyan K, Chernoff D, Bolce R. van Vollenhoven R, et al. Among authors: hambardzumyan k. Ann Rheum Dis. 2014 Nov;73(11):e73. doi: 10.1136/annrheumdis-2014-206383. Epub 2014 Aug 28. Ann Rheum Dis. 2014. PMID: 25169731 No abstract available.
Association of serum anti-centromere protein F antibodies with clinical response to infliximab in patients with rheumatoid arthritis: A prospective study.
Lourido L, Ruiz-Romero C, Picchi F, Diz-Rosales N, Vilaboa-Galán S, Fernández-López C, Tasende JAP, Pérez-Pampín E, Regueiro C, Mera-Varela A, Gonzalez A, Hambardzumyan K, Saevarsdottir S, Nilsson P, Blanco FJ. Lourido L, et al. Among authors: hambardzumyan k. Semin Arthritis Rheum. 2020 Oct;50(5):1101-1108. doi: 10.1016/j.semarthrit.2020.06.010. Epub 2020 Jun 30. Semin Arthritis Rheum. 2020. PMID: 32920323
12 results